LY-3437943 · 40 mg / 3 mL pen- ·Pre-filled 40 mg / 3 mL pen
- ·Alcohol swabs
Retatrutide 40 mg pen
Triple-receptor agonist — pre-filled research pen, 4 × 10 mg.
Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors. The 40 mg pen is the highest-dose presentation in the Omega Grade catalogue — pre-reconstituted for researchers running extended protocols.
What the peptide is.
Retatrutide (LY-3437943) is an investigational once-weekly triple agonist at the GLP-1, GIP, and glucagon receptors, currently in Phase 3 (TRIUMPH programme) under Eli Lilly. The 39-amino-acid peptide carries a C20 fatty-diacid moiety that extends plasma half-life via albumin binding.
The pre-filled pen presentation matches the clinical format used in investigational trials. Omega Grade supplies lyophilised active peptide in clinical-grade pens sourced from Zapopharma, manufactured to a ≥ 99.2% purity specification verified independently by Janoshik Analytical.
Retatrutide is not approved anywhere and is not a medicine. The material is strictly for in vitro research, analytical method development, and reference-standard use.
Dose-dependent agonism at the GLP-1, GIP, and glucagon receptors. The GLP-1 and GIP components are shared with tirzepatide; the added glucagon-receptor agonism is proposed to increase energy expenditure and hepatic fatty-acid oxidation in preclinical models.
Reconstitution, storage, and handling.
Lab-technical guidance for the researcher handling the material. Not therapeutic dosing, not administration guidance — those are not within the scope of this supply.
- Recommended solvent
- Pre-reconstituted — no solvent required
- Typical volume
- N/A (pen)
- The pen is shipped cold-chain and must be refrigerated on receipt.
- Gentle swirl if any settling is observed before first use.
- Lyophilised
- Pre-filled pen — store 2–8 °C. Pen is shipped cold-chain; after first use it may be kept at 2–8 °C.
- Reconstituted
- Pens are pre-reconstituted. Once opened, use within the manufacturer-stated window (typically 4 weeks refrigerated).
- Shelf life · sealed
- See pen label — typically 18–24 months sealed under refrigeration.
- Shelf life · reconstituted
- Once pen is opened: ~4 weeks at 2–8 °C.
- ▸Cold-chain dispatch. Temperature logger included.
- ▸Do not freeze the pen — freeze-thaw compromises pen mechanics.
- ▸Discard sharps in compliant container.
This lot, documented.
Every shipment is accompanied by a signed four-page analytical report including the HPLC chromatogram, ESI-MS spectrum, purity calculation, and sample handling chain-of-custody.
The report you will receive is specific to the lot dispatched to you. The display below is a current representative example.
04:22:11▸lot 26-04-A received ┈ 5.00 g04:22:40▸weight check ┈ PASS ±0.4 mg04:23:12▸sample → janoshik ┈ 50 mg04:23:12▸tracking #jnk-921833405:18:03▸HPLC result ┈ 99.24 %05:18:04▸MS obs 4729.42 Da ┈ PASS05:18:05▸coa.pdf signed ┈ attached05:18:06▸lot approved ┈ LIVE
REPORT ID JA-26-04-012
SUBJECT Retatrutide 40 mg pen
DESIGNATION LY-3437943
LOT 26-04-A
METHOD RP-HPLC, ESI-MS
COLUMN C18, 250 x 4.6 mm, 5 um
MOBILE PHASE A: 0.1% TFA in H2O
B: 0.1% TFA in ACN
GRADIENT 5 -> 65% B over 20 min
FLOW RATE 1.0 mL/min
DETECTION UV 214 nm
INJECTION 20 uL @ 0.5 mg/mL
---
PURITY (A%) 99.20
MASS EXP. 4729.40 Da
MASS OBS. 4729.42 Da
---
CONCLUSION Identity CONFIRMED · Purity PASS
SIGNED BY J. Novak, MSc · Janoshik Analytical SVK
DATE 2026-04-11Registered clinical investigation.
Links below resolve to the ClinicalTrials.gov registry. Trial status reflects publicly disclosed information at the time of publication.
| NCT | Phase | Title | Status | |
|---|---|---|---|---|
| NCT05929066 | Phase 3 | TRIUMPH-1: Retatrutide in obesity | Ongoing | Registry ↗ |
| NCT05936151 | Phase 3 | TRIUMPH-OUTCOMES: cardiovascular outcomes | Ongoing | Registry ↗ |
Research references for Retatrutide 40 mg pen.
3 peer-reviewed publications. Links resolve to PubMed. DOIs are provided where available.
- [01]Jastreboff AM, Kaplan LM, Frías JP, et al.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023 - [02]Rosenstock J, Frias J, Jastreboff AM, et al.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes
The Lancet · 2023 - [03]Coskun T, Urva S, Roell WC, et al.
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist
Cell Metabolism · 2022
- Q.Why is this supplied as a pen rather than a vial?
- A.The pen format matches the clinical formulation used in Eli Lilly's Phase 3 investigational trials, making it the closest-to-reference analytical standard available in research supply. It is pre-reconstituted and cold-chain shipped.
- Q.Is the pen identical to the TRIUMPH clinical device?
- A.The active peptide and basic delivery format are equivalent. It is not a clinical device and is not intended for human administration.
This peptide is supplied by Omega Grade for in vitro laboratory research use. It is not a drug, food, cosmetic, or dietary supplement. It is not approved by the FDA, EMA, MHRA, PMDA, or any other regulatory authority for any therapeutic indication.
No claim of therapeutic benefit is made or implied. The material is not intended for human or veterinary consumption, administration, or any form of self-experimentation. By purchasing, you acknowledge the researcher terms and accept full responsibility for local import compliance and all handling.
Often considered alongside.
Retatrutide 30 mg kit
Triple-receptor agonist — 30 mg vial, full research kit.
- Form
- Lyophilised kit
- Dose
- 30 mg / vial
- Purity
- ≥ 99.2%
Retatrutide 10 mg kit
Triple-receptor agonist — 10 mg vial, full research kit.
- Form
- Lyophilised kit
- Dose
- 10 mg / vial
- Purity
- ≥ 99.2%
Cagrilintide 10 mg
Long-acting amylin analogue — GLP-1 stack partner.
- Form
- Lyophilised kit
- Dose
- 10 mg / vial
- Purity
- ≥ 98.5%